Angiogenesis or formation of new blood vessels in the pre-existing vascular system, is a decisive event leading to tumor growth and metastasis.4 Studies show that the activation of the vascular endothelial growth factor receptor-2 (VEGFR2),5 a crucial target of angiogenesis, initiates the recruitment and migration of endothelial cells to the tumor.6 Therefore, in certain cancers, treatment with VEGFR2 inhibitors can have anti-angiogenic effect.7 The gene discussed is KDR; the disease is neoplasm.